Red Queen Bio Raises $36 Million to Battle Viruses with AI-Designed Antibodies

Red Queen Bio, an OpenAI-backed startup, has secured $36 million to develop AI-designed antibody drugs targeting viruses like bird flu. The company plans clinical trials by 2027 and aims to expand to coronaviruses and Ebola-like pathogens. CEO Nikolai Eroshenko emphasizes enhancing biological defenses against evolving threats. Red Queen avoids dangerous gain-of-function research, joining other AI biosecurity initiatives.